荧光原位杂交技术检测乳腺癌Her-2/neu扩增

目的：探讨荧光原位杂交技术（FISH）检测乳腺癌Her-2/neu的扩增情况,比较FISH法与免疫组织化学（I HC）法检测结果的一致性。方法：收集乳腺癌患者手术切除的肿瘤标本50例。经石蜡包埋,组织切片后,应用FISH法检测Her-2/neu扩增情况,I HC法检测Her-2/neu蛋白表达情况,并对两种检测方法的结果进行统计学分析。结果：50例标本中FISH阳性17例,FISH阴性33例,FISH阳性率34%（17/50）。50例标本中I HC（～）14例,I HC（0～＋）36例,I HC蛋白表达率28%（14/50）。FISH法与I HC法检测结果的总符合率为82%（41/50）（K=0.581）。结论：FISH法具有较高的稳定性与可靠性,临床开展FISH法检测Her-2/neu基因扩增情况作为I HC法的补充,可以更加准确和客观地对乳腺癌患者的治疗和预后进行评价。

The Detection of Her-2/neu Amplification by Fluorescence in Situ Hybridization in Breast Cancer

Objective： To explore the amplification of Her-2/neu in breast cancer by fluorescence in situ hybridization（FISH） and compare to immunohistochemistry（IHC）.Methods： Cancer tissue samples were collected from 50 patients with breast cancer.FISH was applied to detect the amplification of Her-2/neu and IHC was used to assess the protein expression.Then Kappa test was used to compare the results of two methods.Results： Her-2/neu amplification was detected in 50 samples by FISH.Seventeen samples were positive,33 samples were negative.The amplification rate of Her-2/neu was 34%（17/50）.While the analysis of the protein expression of HER-2/neu by IHC,14 samples were positive（-）,33 samples were negative（0-＋）.The positive expression rate of Her-2/neu was 28%（14/50）.The coincident rate of two methods was 82%（41/50）.There was a positive correlation between the two techniques（K=0.581）.Conclusion： FISH technique can help to improve the stability and accuracy for Her-2/neu protein.It should be applied for the pathological diagnosis,prognosis evaluation and clinical treatment of breast cancer.